{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T14:04:08Z","timestamp":1771250648288,"version":"3.50.1"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T00:00:00Z","timestamp":1650672000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The first SARS\u2010CoV\u20102 vaccination campaign in Turkey has started in mid\u2010January for the healthcare workers (HCWs) with the inactive virus vaccine CoronaVac (Sinovac). After four and a half months, the Turkish Ministry of Health rolled out a booster\u2010dose vaccination campaign for HCWs and all people over 50 years old beginning in July 2021. The individuals eligible were given the choice of either CoronaVac or mRNA vaccine BNT162b2 for the third booster\u2010dose vaccination. This study aimed to evaluate SARS\u2010CoV\u20102 IgG antibody titers against the S1 subunit of the spike protein as a marker of the humoral response in 179 HCWs who received a third booster dose of either CoronaVac or BNT162b2. A total of 136 HCWs, 71 female (52.2%) and 65 male (47.8%), completed both serum collections on Days 0 and 28. The median SARS\u2010CoV\u20102 IgG S Protein (SP)\u00a0titer in all participants before the vaccination was 175.7\u2009AU\/ml. Of 136 HCWs, 103 (75.73%) chose BNT162b2 vaccine and 33 (24.26%) chose CoronaVac as the third booster dose. There was a significant difference between the BNT162b2 group and the CoronaVac group in terms of SARS\u2010CoV\u20102 IgG SP titers (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). The median SARS\u2010CoV\u20102 IgG SP titers in BNT162b2 group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009103) and in CoronaVac group (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200933) were 17619.3\u2009AU\/ml and 1153.0\u2009AU\/ml, respectively. The third booster dose with BNT162b2 and CoronaVac increased antibody titers in each participant a mean of 162\u2010fold and 9\u2010fold, respectively. HCWs in the BNT162b2 group reported more frequent adverse events than HCWs in the CoronaVac group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001).\n                  <\/jats:p>","DOI":"10.1002\/jmv.27794","type":"journal-article","created":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T22:43:38Z","timestamp":1650235418000},"page":"3768-3775","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["SARS\u2010CoV\u20102 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-8399","authenticated-orcid":false,"given":"Erdin\u00e7","family":"Yavuz","sequence":"first","affiliation":[{"name":"Department of Family Medicine Samsun University School of Medicine Samsun Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-4123","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"G\u00fcnal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Samsun University School of Medicine Samsun Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8235-9524","authenticated-orcid":false,"given":"E\u015fe","family":"Ba\u015fbulut","sequence":"additional","affiliation":[{"name":"Department of Microbiology Samsun Training and Research Hospital Samsun Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8981-6871","authenticated-orcid":false,"given":"Ahmet","family":"\u015een","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Samsun Training and Research Hospital Samsun Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32318-7"},{"key":"e_1_2_8_3_1","first-page":"1001","article-title":"Confronting the Delta variant of SARS\u2010CoV\u20102, Summer 2021","volume":"18","author":"Rio C","year":"2021","journal-title":"JAMA"},{"key":"e_1_2_8_4_1","unstructured":"RitchieH MathieuE Rod\u00e9s\u2010GuiraoL et al.\u00a0Coronavirus Pandemic (COVID\u201019). Our World in Data; 2021. Accessed 5 December 2021.\u00a0https:\/\/ourworldindata.org\/coronavirus\/country\/united-states?country=USA%7ETUR%7EFRA%7EISR"},{"key":"#cr-split#-e_1_2_8_5_1.1","unstructured":"Coronavirus Disease 2019 (COVID\u201019). Centers for Disease Control and Prevention"},{"key":"#cr-split#-e_1_2_8_5_1.2","unstructured":"2021. Accessed December 5 2021.\u00a0https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/variants\/variant-info.html#Concern"},{"key":"e_1_2_8_6_1","unstructured":"COVID\u201019 (SARS\u2010CoV\u20102) variants. GOV.UK; 2021.\u00a0Accessed December 5 2021.\u00a0https:\/\/www.gov.uk\/government\/collections\/new-sars-cov-2-variant."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00755-z"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00568-5"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00813-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26672-3"},{"key":"e_1_2_8_12_1","unstructured":"CDC.COVID\u201019 vaccines for moderately to severely immunocompromised people.Cdc.gov;2021. Accessed December 6 2021.https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations\/immuno.html"},{"key":"e_1_2_8_13_1","unstructured":"Coronavirus (COVID\u201019) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals. U.S. Food and Drug Administration; 2021. Accessed December 5 2021.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised"},{"key":"e_1_2_8_14_1","unstructured":"COVID\u201019 Booster Shot. Centers for Disease Control and Prevention; 2021. Accessed December 5 2021.\u00a0https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/booster-shot.html"},{"key":"e_1_2_8_15_1","unstructured":"A country\u2010by\u2010country guide to coronavirus vaccine booster plans. POLITICO; 2021. Accessed December 5 2021.\u00a0https:\/\/www.politico.eu\/article\/vaccine-booster-coronavirus-covid-19-europe-delta-varian-who\/"},{"key":"e_1_2_8_16_1","unstructured":"Turkey's national immunization program. Gov.tr. Accessed December 6 2021.\u00a0https:\/\/covid19asi.saglik.gov.tr\/EN-80229\/turkeys-national-immunization-program--.html"},{"key":"e_1_2_8_17_1","unstructured":"LoasanaNA. Indonesia begins to give third COVID\u201019 shots to 1.5 million health workers.Jakarta Post. Accessed December 6 2021.https:\/\/www.thejakartapost.com\/news\/\/08\/02\/indonesia-begins-to-give-third-covid-19-shots-to-1-5-million-health-workers.html"},{"key":"e_1_2_8_18_1","unstructured":"SARS\u2010CoV\u20102 Immunoassay. Accessed 6 December 6 2021.https:\/\/www.corelaboratory.abbott\/int\/en\/offerings\/segments\/infectious-disease\/sars-cov-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27098"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1953344"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27318"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27334"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27350"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00388-21"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03500321"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00169-1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.05.041"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.12339"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055611"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01542-z"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2021.08.010"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103251"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108860"},{"issue":"1633","key":"e_1_2_8_34_1","first-page":"145","article-title":"Third dose of mRNA\u2010based COVID\u201019 vaccines for immunocompromised persons","volume":"63","author":"In brief","year":"2021","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00274-X"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01699-8"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.08.052"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114114"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.08.031"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114255"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01429-X"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7039e4"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmv.27794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.27794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:04:09Z","timestamp":1771247049000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.27794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,23]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/jmv.27794"],"URL":"https:\/\/doi.org\/10.1002\/jmv.27794","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,23]]},"assertion":[{"value":"2021-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}